Zobrazeno 1 - 8 of 8 pro vyhledávání: '"Cheng Seok Quah"'
1
First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced urothelial carcinoma (UC) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations
Autor: Benjamin Garmezy, Cesar Augusto Perez, Shumei Kato, Manish Sharma, Cheng Seok Quah, Betty Tam, Paul Severson
Publikováno v: Journal of Clinical Oncology. 41:TPS593-TPS593
TPS593 Background: FGFR1-4 gene alterations are infrequent across solid tumors though preclinical and clinical evidence indicate activating alterations drive oncogenesis and tumor growth. They can be found in up to 20% of patients with UC and up to 3
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1515db7b657a514794b28ef966e4960b
https://doi.org/10.1200/jco.2023.41.6_suppl.tps593
Zobrazit plný text záznamu
2
First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations
Autor: James J. Harding, Cesar Augusto Perez, Shumei Kato, Manish Sharma, Benjamin Garmezy, Cheng Seok Quah, Betty Tam, Paul Severson
Publikováno v: Journal of Clinical Oncology. 41:TPS637-TPS637
TPS637 Background: FGFR1-4 gene alterations are infrequent across solid tumors though preclinical and clinical evidence indicate activating alterations drive oncogenesis and tumor growth. Pharmacological inhibition of FGFR1-4 leads to tumor shrinkage
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::446f3770f468af7e9b81f50f41791374
https://doi.org/10.1200/jco.2023.41.4_suppl.tps637
Zobrazit plný text záznamu
3
ARC-9: Phase Ib/II study to evaluate etrumadenant (AB928)-based treatment combinations in patients with metastatic colorectal cancer (mCRC)
Autor: Nick Giafis, Kartik Krishnan, Michael Cecchini, Johanna C. Bendell, Jennifer Scott, Cheng Seok Quah
Publikováno v: Journal of Clinical Oncology. 39:TPS150-TPS150
TPS150 Background: ATP release from dying cancer cells in response to platinum-based chemotherapy increases extracellular immunosuppressive adenosine, which binds and activates the A2a and A2b receptors on immune cells. Adenosine-mediated signaling i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::95f9b677b2017fcf447a9d0533da133e
https://doi.org/10.1200/jco.2021.39.3_suppl.tps150
Zobrazit plný text záznamu
4
ARC-8: Phase I/Ib study to evaluate safety and tolerability of AB680 + chemotherapy + zimberelimab (AB122) in patients with treatment-naive metastatic pancreatic adenocarcinoma (mPDAC)
Autor: Zev A. Wainberg, Daniel DiRenzo, Lixia Jin, Kartik Krishnan, Wade Berry, Jennifer Scott, Cheng Seok Quah, Nick Giafis, Johanna C. Bendell, Kimberline Gerrick, Gulam Abbas Manji, Akshata Udyavar
Publikováno v: Journal of Clinical Oncology. 39:404-404
404 Background: AB680, a potent, selective small-molecule inhibitor of soluble and membrane-bound CD73, targets a major pathway of extracellular adenosine production with the aim of eliminating adenosine-mediated immunosuppression within the tumor mi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1cb0f022f82499a4f06ec34b3187bd9d
https://doi.org/10.1200/jco.2021.39.3_suppl.404
Zobrazit plný text záznamu
6
Phase 2 study of acalabrutinib in ibrutinib (IBR)-intolerant patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
Autor: Kerry A. Rogers, Raquel Izumi, Jeff Porter Sharman, Rakesh Raman, Thomas J. Kipps, Morton Coleman, Philip A. Thompson, Min Hui Wang, Cheng Seok Quah, John N. Allan, Bruce D. Cheson, Melanie M. Frigault
Publikováno v: Journal of Clinical Oncology. 37:7530-7530
7530 Background: In CLL pts treated with the Bruton tyrosine kinase (BTK) inhibitor IBR, the most common reason for discontinuation was adverse events (AEs; 50%-63%; Mato et al, 2018). This Phase 2 trial evaluated acalabrutinib, a highly selective, p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::18abdcf434a77680ea3580ceb9fb891c
https://doi.org/10.1200/jco.2019.37.15_suppl.7530
Zobrazit plný text záznamu
7
Assessment of single-institution HER2 testing patterns, rate of HER2+ disease, and utilization of trastuzumab in early breast cancer
Autor: Sudhir Unni, K.R. Saverno, Diana I. Brixner, Hillevi Bauer, Mukul Singhal, Minkyoung Yoo, Anthony Masaquel, David D. Stenehjem, Cheng Seok Quah
Publikováno v: Journal of Clinical Oncology. 31:124-124
124 Background: Improved outcomes with HER2-directed therapies highlight the importance of standardized testing for HER2 positivity. This study aimed to assess HER2 testing practices, rate of HER2+ disease, and trastuzumab use in early breast cancer
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2cf4f1e3a9edc63fd6d414ce81b444e2
https://doi.org/10.1200/jco.2013.31.31_suppl.124
Zobrazit plný text záznamu
8
Treatment (tx) patterns and clinical outcomes for patients (pts) with de novo versus recurrent HER2+metastatic breast cancer (MBC)
Autor: Bongin Yoo, Musa Mayer, Hope S. Rugo, Debu Tripathy, Adam Brufsky, Peter A. Kaufman, Marianne Ulcickas Yood, Denise A. Yardley, Cheng Seok Quah
Publikováno v: Web of Science
523 Background: Use of adjuvant trastuzumab (T) in pts with HER2+ early breast cancer is associated with decreased recurrence. As fewer patients relapse, the proportion of pts with de novo metastatic disease in the first-line (1L) setting will increa
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f0b7c2a4a1f80055842f1e5dbee3e5e
https://publons.com/wos-op/publon/29619530/
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje